Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News |  Radiopharmaceuticals Market 2017 - Global Industry Size, Analysis, Growth, Opportunity Report"Global Radiopharmaceuticals Market" is projected to reach USD 9.49 billion by 2024 from USD 4.87 billion in 2016, at a CAGR of 8.7% .
Full Report Access @ : http://databridgemarketresearch.com/ Radiopharmaceuticals Market : Recent Developments Recent trends in the radiopharmaceuticals marketsuch as growing disease which targeted cancer therapy,increasing awareness, expanding applications ofmolecular imaging,technologicaladvancement, increasing trend of radio-labelled peptides and monoclonal antibodies for the diagnosis and treatment of cancer tumors and increasing use of SPECT & PET scans is expected to drive the market in the forecast period 2017 to 2024. Radiopharmaceuticals are mostly used for treatment of cancer, bone pain, and thyroid cancer. In the U.S. cancer is second fatal disease whereas in the UK it is the leading cause of death. In most of the third (https://en.wikipedia.org/ On the other hand, shorter half life of radiopharmaceuticals, stringent regulatory guidelines and competition from conventional diagnostic procedures are some of the factors which may hinder the growth of radiopharmaceuticals market. Request for sample report @ : http://databridgemarketresearch.com/ Radiopharmaceuticals Market: Segmentation The global radiopharmaceuticalsmarket is segmented based on type, procedural volumes, application, sources, end-user,and geography. On the basis of type, the radiopharmaceuticals market is sub-segmented into diagnostic and therapeutic radiopharmaceuticals. On the basis of procedural volumes, the radiopharmaceuticals market is sub-segmented into diagnostic procedures and therapeutic procedures. On the basis of application, the global radiopharmaceuticals market is sub-segmented into diagnostic application and therapeutic application. Diagnostic application are further sub-segmented into single-photon emission computed tomography (SPECT) and positron emission tomography (PET). Single-photon emission computed tomography (SPECT) includes cardiology, lymphoma, thyroid, neurology and others. Radiopharmaceuticals Market – Geographical Segmentation: Based on geography, the market is segmented into five geographical regions, North America, Europe, Asia-Pacific, South America and Middle East and Africa. The geographical regions are further segmented into 29major countries such as U.S. Canada, Mexico, Germany, France, U.K., Belgium, Switzerland, Belgium, Turkey, Japan, China, Singapore, Brazil, India, Russia, South Africa and others.In 2017, North Americais expected to dominate the radiopharmaceuticals market with more than 42.5%market share with a share of 4.7% followed by Europeand Asia-Pacific. However the Asia-Pacificregion is expected to grow at the highest CAGR in the forecast period 2017 to 2024. This can be due to the rising demand of PET scanners and high production of radiopharmaceuticals for therapeutic purposes in India, aging population,rising patient awareness,increasing healthcare expenditure in Japan and China, and initiatives by the Australian government. Inquire before buying report @ : http://databridgemarketresearch.com/ Radiopharmaceuticals Market – Company Share Analysis: The radiopharmaceuticals market report contains an in-depth profiling of the key market players, along with the recent developments (new product launches, partnerships, agreements, collaborations, and joint ventures) and strategies adopted by them to sustain and strengthen their position in the market. Some examples of recent strategies/developments are: In May2017, Advanced Accelerator Applications (AAA) and Blue Earth Diagnostics Ltd entered into a non-exclusive manufacturing agreement and an exclusive distribution agreementfor the supply of Blue Earth Diagnostics' PET imaging product Axumin (fluciclovine (18F)) in France, Germany, Spain, Italy, and Portugal.Axumin is indicated in Europe for use in Positron Emission Tomography (PET) imaging for the detection of recurrence of prostate cancer. Some of the major players operating in the global radiopharmaceuticals market are : · Cardinal Health Inc. · MallinckrodtPlc. · GE Healthcare · Lantheus Medical Imaging Inc. · Bayer AG · Bracco Imaging SpA · Eczacibasi-Monrol Nuclear Products · Nordion Inc. · Advanced Accelerator Applications S.A. · IBA Molecular Imaging · CovidienPlc · Positron Corporation · NTP Radioisotopes Pty. Ltd. · Advanced Medical Isotope Corporation · Avid Radiopharmaceuticals · Jubilant Pharma · Actinium Pharmaceuticals Inc. · AREVA Meds · Immunomedics Inc. · Merck& Co. Inc. · Navidea Browse Related Reports : Global Cancer Biomarkers Market, By Tumor (Breast, Lung, Prostate), By Type (Protein Biomarker, Genetic Biomarkers), By Profiling Technology (Proteomics, Genomics, Imaging, Immunoassay) Report Access : http://databridgemarketresearch.com/ About Data Bridge Market Research: Data Bridge Market Research (http://databridgemarketresearch.com/) Contact: Vishal Dixit Data Bridge Market Research Tel: +1-888-387-2818 Email: Sales@databridgemarketresearch.com Investor: investors@databridgemarketresearch.com Visit Blog: http://databridgemarketresearch.com/ Follow us on LinkedIn: https://www.linkedin.com/ End
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number